menu
    • menu

    Company profile for Novartis Pharmaceuticals Corporation

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Our Pharma US Business Novartis Pharmaceuticals Corporation (NPC) – a US affiliate of Basel, Switzerland-based Novartis AG – is committed to the research and development and marketing of patent-protected medicines and treatments for helping patients and improving patient care. We do business responsibly and we adhere to the highest ethical standards as outlined in the Novartis Code of Conduct. At Novartis Pharmaceuticals ...
    Our Pharma US Business Novartis Pharmaceuticals Corporation (NPC) – a US affiliate of Basel, Switzerland-based Novartis AG – is committed to the research and development and marketing of patent-protected medicines and treatments for helping patients and improving patient care. We do business responsibly and we adhere to the highest ethical standards as outlined in the Novartis Code of Conduct. At Novartis Pharmaceuticals Corporation, we believe that all Americans deserve access to quality health care, including prescription medicines, health education about their disease or condition

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Novartis Pharmaceuticals CorporationSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Klybeckstrasse 141, CH-4057, Basel
    Telephone
    Telephone
    +41 61 324 11 11
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.novartis.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    “Our unmatched efficiency and track record of faster DMF filings give our customers a critical competitive advantage”

    “Our unmatched efficiency and track record of faster DMF filings give our customers a critical competitive advantage”

    This week, SpeakPharma interviews Pete Werth III, the new president of ChemWerth, a company that has been at the forefront of the generic pharmaceutical industry for over four decades. He shares his vision for ChemWerth, which includes his commitment to strengthening global manufacturing relationships, and enhancing supply chain resilience. Additionally, he highlights the key aspects of a successful drug master file (DMF). HIGHLIGHTS// Pete Werth III, the new president of ChemWerth/ vision for ChemWerth/ commitment to strengthening global manufacturing relationships/ key aspects of a successful drug master file Your father, Peter J. Werth, is recognized as one of the founders of the generic pharmaceutical industry, having built ChemWerth from the ground up over four decades ago. How do you view his legacy? As you take the helm, what key lessons or principles from his leadership do you intend to carry forward? My father, Peter J. Werth, is a true pioneer in the generic pharmaceutical industry. Over his 42‐year tenure, he not only built ChemWerth from a humble garage startup into a global leader in generic API development but also established standards that many in our industry now take for granted. Under his leadership, we filed our very first DMF in 1987 and have since achieved more than 500 DMF filings. With an average review cycle of just 0.79, we have been far outperforming the industry average of 2.5 cycles. His focus on quality, regulatory excellence, and a relentless commitment to customers’ success set the foundation for our reputation as a trusted supplier of over 500 APIs sourced from more than 30 cGMP-certified facilities worldwide. Equally inspiring is his dedication to nurture long-term, mutually beneficial relationships with manufacturing partners across the US, Europe, India, and China, as well as his passion for giving back to the community through philanthropic initiatives. As I take the helm, I intend to build on his guiding principles — sustaining our high standards of quality and compliance while pursuing innovation in regulatory strategy, diversifying our supply chain, and embracing new technologies and approaches to remain competitive in an evolving market. I will also strive to continue his legacy of mentorship, ensuring that our company culture remains rooted in integrity and diligence, with an unyielding focus on making safe, affordable medicines available worldwide. HIGHLIGHTS// trusted supplier of over 500 APIs/ 30 cGMP-certified facilities worldwide/ embracing new technologies and approaches to remain competitive What are your top priorities as the new president of ChemWerth? How do you plan to strengthen and expand relationships with manufacturers worldwide? My immediate priorities as the new president are twofold: to enhance the value we deliver to our customers and, to deepen our relationships with our manufacturing partners worldwide. We will further diversify our supply chain and broaden our product portfolio. Our expansion plans include upgrading equipment, and hiring additional highly skilled scientists, engineers, and GMP auditors. We will also leverage our proprietary product selection and regulatory submission processes. These processes help us get the regulatory filing right the first time, and allows us to be approved 44 percent faster than the industry average. This helps our customers gain a competitive edge in the market. In essence, by strengthening operational excellence and expanding our global network, we intend to continue the company’s long-standing commitment to customer success and process innovation. We plan to reinforce our long-standing relationships with our manufacturers — especially those in strategic markets like China and India — by helping our partners meet the highest standards of regulatory compliance and current good manufacturing practice (cGMP) quality. This balanced approach of strengthening existing partnerships while pioneering new ones is key to maintaining and growing our competitive edge. HIGHLIGHTS// diversify our supply chain and broaden our product portfolio/ commitment to customer success and process innovation/ filings approved 44 percent faster than the industry average When ChemWerth last spoke to PharmaCompass, there was a mention of investing millions of dollars in expanding manufacturing partnerships in China and India. Can you elaborate on the success of these partnerships, and how have they contributed to ChemWerth’s overall growth? Our strategic, multimillion-dollar investments in manufacturing partnerships are a cornerstone of our growth strategy. Over the past few years, these joint ventures have proven their worth by diversifying our supply base and mitigating the risk of global supply chain disruptions — a lesson that became all too clear during the Covid-19 pandemic. These investments are already paying dividends. They help us support manufacturers producing steroids, hormones, veterinary products, and large-volume APIs, while also accelerating the development of small-molecule inhibitors and new generic APIs. We have ensured that our partners are equipped with the latest equipment and trained personnel to meet cGMP standards. By partnering with facilities in these markets, we now have access to state-of-the-art production capabilities that enable us to produce a wider range of APIs at competitive costs. The success of these partnerships is evident in our ability to consistently file DMFs rapidly — often on the first cycle — and deliver affordable, high-quality medicines to patients worldwide. This supports our clients’ growth trajectory and has helped us expand into new markets. This strategy has reinforced our global footprint — supporting our presence in 38 countries with over 100 products — and positioned us well to capitalize on a global generic drug market projected to grow at a compounded annual growth rate of 5.4 percent from 2022 to 2030, to reach a size of US$ 671 billion by 2030. HIGHLIGHTS// strategic multimillion-dollar investments/ support manufacturers producing steroid, hormone, veterinary products/ development of small-molecule inhibitors and new generic APIs/ ensured partners are equipped with the latest equipment and trained personnel ChemWerth has an impressive track record, and an over 40-year relationship with the US Food and Drug Administration (FDA). What are the key aspects of a successful DMF? Are there specific challenges manufacturers face in preparing DMFs, and how does ChemWerth help them overcome these hurdles? ChemWerth’s record of filing over 500 DMFs in 38 countries reflects our commitment to excellence in regulatory compliance and quality management. A successful DMF is built on comprehensive documentation that rigorously follows cGMP guidelines, robust analytical validation, and detailed tracking of every step. Every DMF we file meticulously details the entire manufacturing process — from raw material acquisition to final batch production. This comprehensive approach ensures that our submissions meet the rigorous quality, safety, and efficacy standards expected by the FDA. Our team stays continuously updated on the evolving guidelines and protocols, which allows us to file DMFs that align with current FDA practices. We recognize that many manufacturers face challenges such as complex regulatory requirements, lengthy review cycles, and the need for precise coordination between various production stages. ChemWerth helps them overcome these hurdles by offering end-to-end regulatory support, detailed internal audits, and continuous training on cGMP and FDA requirements. Our efficiency is a critical competitive advantage. By receiving approvals 44 percent faster than the industry average, we help our customers get their products to market faster, resulting in larger market share and increased profits. HIGHLIGHTS// over 500 DMFs in 38 countries/ robust analytical validation/ end-to-end regulatory support What is your vision for ChemWerth over the next few years? How do you plan to navigate the challenges and opportunities in the generic pharmaceutical industry? I plan to continue to add value for our customers, and look for innovative ways to compete in today’s generic pharmaceutical landscape. At ChemWerth, our vision for the future is rooted in both our proud legacy and our relentless drive for innovation. We will further diversify our supply chain and expand our product portfolio. We have begun leveraging our expertise to supply APIs for biosimilars and new drug applications (NDAs), while maintaining our reputation for rapid regulatory approvals. With unwavering determination, we uphold our “First to Quality. Fast to Market.” approach — delivering high-quality APIs to customers worldwide while leveraging our expertise to give them a competitive edge in their markets. HIGHLIGHTS// supply APIs for biosimilars and NDAs/ give customers a competitive edge in their markets 

    Impressions: 555

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage

    Radio Compass
    12 Mar 2025
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    AI drug discovery market to grow 30% CAGR, to reach US$ 35 bn by 2034; Novo, Lilly, BMS forge deals

    AI drug discovery market to grow 30% CAGR, to reach US$ 35 bn by 2034; Novo, Lilly, BMS forge deals

    Artificial intelligence (AI) is emerging as a transformative force in drug discovery and development. The global AI in drug discovery market was valued at US$ 1.99 billion in 2024 and is estimated to reach US$ 2.65 billion in 2025. Going forward, the market is expected to grow at an impressive compounded annual growth rate (CAGR) of 29.6 percent, to reach a market size of US$ 35.42 billion by 2034, says a report by Polaris Market Research. This growth expectation mirrors the eagerness within the biopharma industry to leverage AI in order to overcome the traditional barriers of lengthy timelines, exorbitant costs, and high failure rates. This eagerness is also being manifested in deal making — Big Pharma has been busy forging alliances with AI-driven drug discovery companies. Over the last two years, almost every big drugmaker, including Novo Nordisk, Merck, BMS, Pfizer, AstraZeneca, Otsuka Pharmaceutical, Novartis and Sanofi, has signed deals with various AI drug discovery companies. PharmaCompass' compilation shows there are scores of molecules discovered by AI currently in discovery and developmental phases, demonstrating the technology's growing impact on pharmaceutical pipelines.  Access the Dashboard on AI-Discovered Drug Candidates (Free Excel Available) Novo, Lilly, BMS invest in AI partnerships; Recursion, Exscientia merge to create AI powerhouse With the transformative potential of AI becoming increasingly evident, we witnessed a slew of deals in the biopharma industry over the last six months. A significant deal in the AI drug discovery space was the merger of two leaders — Recursion and Exscientia — that took place in November last year. Exscientia is now a wholly-owned subsidiary of Recursion. The merger has created a global technology-enabled drug discovery leader with end-to-end capabilities. The merged entity has over 10 clinical and preclinical programs, and around 10 advanced discovery programs in the pipeline.  Apart from this merger, several large drugmakers have struck deals with AI drug discovery firms since September last year. For instance, in January this year, Valo Health and Novo Nordisk expanded their collaboration to discover and develop novel treatments for cardiometabolic diseases. This deal, valued at up to US$ 4.8 billion, aims to harness the power of AI and extensive human datasets. Building on their initial 2023 partnership, it will enable the development of up to 20 drug programs.  Similarly, Pfizer, which is already big on AI, extended its AI drug discovery pact with PostEra and also partnered IgnitionAI to enhance drug discovery — all within the last six months. And Novartis struck a drug discovery deal with Generate BioMedicines in September. Insilico Medicine has been actively forging partnerships. In January, Insilico entered a second exclusive global license agreement with Menarini Group for an AI-discovered preclinical asset targeting high unmet needs in oncology. Insilico also has a tie-up with Sanofi, dating back to 2022. In December 2024, AI Proteins announced a research collaboration and option agreement with BMS to design and optimize mini-proteins for therapeutic use. And in September, Eli Lilly joined hands with Genetic Leap to accelerate the development of genetic medicines. Lilly will leverage Genetic Leap’s RNA-targeted AI platform to generate oligonucleotide drugs against selected targets.  Access the Dashboard on AI-Discovered Drug Candidates (Free Excel Available)  AI leads to faster target identification; Insilico, BenevolentAI’s candidates in trials Computational biology, and especially AI, has fundamentally changed the drug discovery paradigm. The traditional method of drug discovery used to take 13 to 15 years, costing an average of US$ 2.5 billion in investment before a drug got approved and launched in the market. Additionally, less than 10 percent of candidates in phase 1 clinical trials used to end up getting approved by the US Food and Drug Administration (FDA). All that has begun to change. According to Khair ElZarrad, Director of the Office of Medical Policy within FDA’s Center for Drug Evaluation and Research, since 2016, FDA has received approximately 300 submissions that reference AI use as of May 2024. These submissions range from drug development, drug discovery, clinical research, clinical trials as well as post-market safety surveillance and manufacturing. Though we are yet to witness an AI-generated candidate translate into an approved therapy, target identification in drug discovery is visibly becoming a lot faster. This is the process that identifies specific molecules or pathways in the human body that are linked to a disease. The best example of dramatic acceleration of timelines is Insilico Medicine’s development of INS018_055, a candidate for idiopathic pulmonary fibrosis that entered phase 2 trials in June 2023. Using their AI platform PandaOmics, researchers at Insilico compressed target identification from years to just 18 months. Similarly, BenevolentAI successfully employed their AI platform to identify a new target for ulcerative colitis, leading to the development of BEN-8744, a candidate that has been in phase 1a clinical trials since August 2023.  Access the Dashboard on AI-Discovered Drug Candidates (Free Excel Available)  Oncology leads AI drug discovery market; Recursion shows how to repurpose drugs using AI The integration of AI in oncology research has been impactful, accounting for the largest revenue share (about 22.4 percent) in the AI drug discovery market in 2023. AI technologies have accelerated the discovery and development of new cancer treatments, bolstered personalized medicine approaches, and improved clinical trial designs in the arena of this complex disease.  Another promising application is drug repurposing, where AI can identify new therapeutic applications for existing drugs. Recursion Pharmaceuticals’ REC-2282 exemplifies this approach. This therapy is currently in phase 2/3 studies for neurofibromatosis type 2 (a genetic condition that causes tumors to grow along nerves). By repurposing compounds already vetted for safety, this strategy can bypass early-stage failures, reducing both time and cost compared to developing entirely new molecules. However, the use of AI in drug discovery is not without challenges. Exscientia’s EXS-21546, designed to treat solid tumors, entered phase 1/2 trials in 2020 but was discontinued in 2023 after modeling suggested that achieving a suitable therapeutic index would be difficult. Though this is a clinical failure, it highlights AI’s value in identifying potential failures earlier on in the development process, saving resources that would have otherwise been spent on later-stage trials.  Access the Dashboard on AI-Discovered Drug Candidates (Free Excel Available)  Our view The Covid-19 pandemic was a time when humanity felt the urgent need to speed up the process of drug discovery, testing and approvals. It also hastened the process of integrating AI into pharmaceutical research, leading to the launch of Covid vaccines in record time. Today, there is no looking back — AI is bringing about a paradigm shift in how drugs are discovered. With increasing reliance on AI, there is hope that drug discovery will be more accurate, efficient and less time and cost consuming.
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 481

    https://www.pharmacompass.com/radio-compass-blog/ai-drug-discovery-market-to-grow-30-cagr-to-reach-us-35-bn-by-2034-novo-lilly-bms-forge-deals

    #PharmaFlow by PHARMACOMPASS
    13 Mar 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Novartis shareholders approve resolutions at 2025 AGM
    Novartis shareholders approve resolutions at 2025 AGM

    07 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/07/3038987/0/en/Novartis-shareholders-approve-all-resolutions-proposed-by-the-Board-of-Directors-at-the-2025-Annual-General-Meeting.html

    GLOBENEWSWIRE
    07 Mar 2025
    Share Share
    Novartis Presents HS & CSU Data At AAAAI & AAD 2025
    Novartis Presents HS & CSU Data At AAAAI & AAD 2025

    28 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/28/3034762/0/en/Novartis-data-presentations-at-AAAAI-and-AAD-underscore-commitment-to-advancing-treatment-of-hidradenitis-suppurativa-HS-and-chronic-spontaneous-urticaria-CSU.html

    GLOBENEWSWIRE
    28 Feb 2025
    Share Share
    Novartis’ Fabhalta Gets Positive CHMP Opinion For C3G
    Novartis’ Fabhalta Gets Positive CHMP Opinion For C3G

    28 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/28/3034670/0/en/Novartis-oral-Fabhalta-iptacopan-receives-positive-CHMP-opinion-for-the-treatment-of-adults-living-with-C3-glomerulopathy-C3G.html

    GLOBENEWSWIRE
    28 Feb 2025
    Share Share
    HMRI partners with Novartis Australia to supercharge heart health
    HMRI partners with Novartis Australia to supercharge heart health

    19 Feb 2025

    // BIOSPECTRUM

    https://www.biospectrumasia.com/news/47/25603/hmri-partners-with-novartis-australia-to-supercharge-heart-health.html

    BIOSPECTRUM
    19 Feb 2025
    Share Share
    Novartis buys Blackstone's Anthos for up to $3.1 billion
    Novartis buys Blackstone's Anthos for up to $3.1 billion

    12 Feb 2025

    // REUTERS

    https://www.reuters.com/markets/deals/novartis-agrees-acquire-anthos-up-31-bln-2025-02-11/

    REUTERS
    12 Feb 2025
    Share Share
    Novartis gives up on anti-CD40 antibody to treat Sjögren's
    Novartis gives up on anti-CD40 antibody to treat Sjögren's

    01 Feb 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/novartis-gives-anti-cd40-antibody-treat-sjogrens-due-benefitrisk-profile

    FIERCE BIOTECH
    01 Feb 2025
    Share Share

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Novartis oral Fabhalta® (iptacopan) Receives Positive CHMP Opinion

    Details:

    Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway. It is being evaluated for the treatment of patients withC3 glomerulopathy.


    Lead Product(s): Iptacopan Hydrochloride

    Therapeutic Area: Nephrology Brand Name: Fabhalta

    Study Phase: Phase IIIProduct Type: Other Small Molecule

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable February 28, 2025

    blank

    01

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    NextGen Biomed
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    NextGen Biomed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Iptacopan Hydrochloride

    Therapeutic Area : Nephrology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Novartis oral Fabhalta® (iptacopan) Receives Positive CHMP Opinion

    Details : Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway. It is being evaluated for the treatment of patients withC3 glomerulopathy.

    Product Name : Fabhalta

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    February 28, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Alcon Launches New Systane PRO Preservative-Free in The US

    Details:

    Systane Pro PF (propylene glycol) is a one-of-a-kind multi-dose preservative-free triple action formula that hydrates, restores and protects all types of dry eyes.


    Lead Product(s): Mono Propylene Glycol

    Therapeutic Area: Ophthalmology Brand Name: Systane Pro PF

    Study Phase: Approved FDFProduct Type: Other Small Molecule

    Sponsor: Inapplicable

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable February 24, 2025

    blank

    02

    Alcon Inc

    U.S.A
    arrow
    NextGen Biomed
    Not Confirmed

    Alcon Inc

    U.S.A
    arrow
    NextGen Biomed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Mono Propylene Glycol

    Therapeutic Area : Ophthalmology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Alcon Launches New Systane PRO Preservative-Free in The US

    Details : Systane Pro PF (propylene glycol) is a one-of-a-kind multi-dose preservative-free triple action formula that hydrates, restores and protects all types of dry eyes.

    Product Name : Systane Pro PF

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    February 24, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Isomorphic Labs Announces Novartis Collaboration Expansion

    Details:

    IsoLabs and Novartis will expand the scope of the initial collaboration, adding up to three additional research programs to discover small molecule therapeutics against three undisclosed targets.


    Lead Product(s): Undisclosed

    Therapeutic Area: Technology Brand Name: Undisclosed

    Study Phase: Discovery PlatformProduct Type: Other Small Molecule

    Recipient: Isomorphic Labs

    Deal Size: $1,237.5 million Upfront Cash: $37.5 million

    Deal Type: Collaboration February 18, 2025

    blank

    03

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    NextGen Biomed
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    NextGen Biomed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Technology

    Highest Development Status : Discovery Platform

    Recipient : Isomorphic Labs

    Deal Size : $1,237.5 million

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Isomorphic Labs Announces Novartis Collaboration Expansion

    Details : IsoLabs and Novartis will expand the scope of the initial collaboration, adding up to three additional research programs to discover small molecule therapeutics against three undisclosed targets.

    Product Name : Undisclosed

    Product Type : Other Small Molecule

    Upfront Cash : $37.5 million

    February 18, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Novartis to Acquire Anthos Therapeutics for USD 925 Million Upfront

    Details:

    Through the acquisition, Novartis will strengthen its cardiovascular portfolio with Anthos' MAA868 (abelacimab), a potential monoclonal antibody for the treatment of atrial fibrillation.


    Lead Product(s): Abelacimab

    Therapeutic Area: Cardiology/Vascular Diseases Brand Name: MAA868

    Study Phase: Phase IIIProduct Type: Antibody

    Recipient: Anthos Therapeutics

    Deal Size: $3,075.0 million Upfront Cash: $925.0 million

    Deal Type: Acquisition February 11, 2025

    blank

    04

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    NextGen Biomed
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    NextGen Biomed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Abelacimab

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Phase III

    Recipient : Anthos Therapeutics

    Deal Size : $3,075.0 million

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Novartis to Acquire Anthos Therapeutics for USD 925 Million Upfront

    Details : Through the acquisition, Novartis will strengthen its cardiovascular portfolio with Anthos' MAA868 (abelacimab), a potential monoclonal antibody for the treatment of atrial fibrillation.

    Product Name : MAA868

    Product Type : Antibody

    Upfront Cash : $925.0 million

    February 11, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Light Horse Therapeutics Enters Into Strategic Collaboration with Novartis

    Details:

    The collaboration between Novartis and Light Horse offers a remarkable opportunity to utilize a genetic screening platform and proprietary chemical libraries to develop innovative cancer treatments.


    Lead Product(s): Undisclosed

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Discovery PlatformProduct Type: Other Small Molecule

    Recipient: Light Horse Therapeutics

    Deal Size: $1,025.0 million Upfront Cash: $25.0 million

    Deal Type: Collaboration January 09, 2025

    blank

    05

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    NextGen Biomed
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    NextGen Biomed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Oncology

    Highest Development Status : Discovery Platform

    Recipient : Light Horse Therapeutics

    Deal Size : $1,025.0 million

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Light Horse Therapeutics Enters Into Strategic Collaboration with Novartis

    Details : The collaboration between Novartis and Light Horse offers a remarkable opportunity to utilize a genetic screening platform and proprietary chemical libraries to develop innovative cancer treatments.

    Product Name : Undisclosed

    Product Type : Other Small Molecule

    Upfront Cash : $25.0 million

    January 09, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Novartis Phase III Study of Onasemnogene Abeparvovec Meets Primary Endpoint in SMA

    Details:

    Zolgensma (onasemnogene abeparvovec) is USFDA approved, one time gne therapy that acts as SMN1 gene stimulant. It is indicated for the treatment of spinal muscular atrophy.


    Lead Product(s): Onasemnogene Abeparvovec

    Therapeutic Area: Genetic Disease Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Cell and Gene therapy

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable December 30, 2024

    blank

    06

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    NextGen Biomed
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    NextGen Biomed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Onasemnogene Abeparvovec

    Therapeutic Area : Genetic Disease

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Novartis Phase III Study of Onasemnogene Abeparvovec Meets Primary Endpoint in SMA

    Details : Zolgensma (onasemnogene abeparvovec) is USFDA approved, one time gne therapy that acts as SMN1 gene stimulant. It is indicated for the treatment of spinal muscular atrophy.

    Product Name : Undisclosed

    Product Type : Cell and Gene therapy

    Upfront Cash : Not Applicable

    December 30, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    BioAge Partners with Novartis On Age-Related Disease Therapy Target Discovery

    Details:

    The collaboration aims to identify and validate multiple novel therapeutic drug targets by investigating the biological mechanisms related to age-related diseases and conditions.


    Lead Product(s): Undisclosed

    Therapeutic Area: Cardiology/Vascular Diseases Brand Name: 20

    Study Phase: Discovery PlatformProduct Type: Undisclosed

    Recipient: BioAge Labs

    Deal Size: $550.0 million Upfront Cash: $20.0 million

    Deal Type: Collaboration December 18, 2024

    blank

    07

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    NextGen Biomed
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    NextGen Biomed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Discovery Platform

    Recipient : BioAge Labs

    Deal Size : $550.0 million

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    BioAge Partners with Novartis On Age-Related Disease Therapy Target Discovery

    Details : The collaboration aims to identify and validate multiple novel therapeutic drug targets by investigating the biological mechanisms related to age-related diseases and conditions.

    Product Name : 20

    Product Type : Undisclosed

    Upfront Cash : $20.0 million

    December 18, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Minzasolmin Proof-of-Concept Study Shapes UCB Parkinson’s Research Program Next Steps

    Details:

    UCB0599 (minzasolmin), an investigational, oral small molecule, alpha-synuclein misfolding inhibitor, being developed in partnership with Novartis for Parkinson’s disease failed to meet endpoints.


    Lead Product(s): Minzasolmin

    Therapeutic Area: Neurology Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Small molecule

    Recipient: UCB Pharma S.A

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable December 16, 2024

    blank

    08

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    NextGen Biomed
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    NextGen Biomed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Minzasolmin

    Therapeutic Area : Neurology

    Highest Development Status : Phase II

    Recipient : UCB Pharma S.A

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Minzasolmin Proof-of-Concept Study Shapes UCB Parkinson’s Research Program Next Steps

    Details : UCB0599 (minzasolmin), an investigational, oral small molecule, alpha-synuclein misfolding inhibitor, being developed in partnership with Novartis for Parkinson’s disease failed to meet endpoints.

    Product Name : Undisclosed

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    December 16, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Monte Rosa, Novartis Close Deal on VAV1 Molecular Glue for T And B Cell Modulation

    Details:

    Under the licensing agreement, Novartis will gain exclusive global rights to develop, manufacture, and commercialize MRT-6160, currently under study for immune-mediated conditions.


    Lead Product(s): MRT-6160

    Therapeutic Area: Immunology Brand Name: MRT-6160

    Study Phase: Phase IProduct Type: Small molecule

    Recipient: Monte Rosa Therapeutics

    Deal Size: $2,250.0 million Upfront Cash: $150.0 million

    Deal Type: Licensing Agreement December 11, 2024

    blank

    09

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    NextGen Biomed
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    NextGen Biomed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : MRT-6160

    Therapeutic Area : Immunology

    Highest Development Status : Phase I

    Recipient : Monte Rosa Therapeutics

    Deal Size : $2,250.0 million

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Monte Rosa, Novartis Close Deal on VAV1 Molecular Glue for T And B Cell Modulation

    Details : Under the licensing agreement, Novartis will gain exclusive global rights to develop, manufacture, and commercialize MRT-6160, currently under study for immune-mediated conditions.

    Product Name : MRT-6160

    Product Type : Small molecule

    Upfront Cash : $150.0 million

    December 11, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Novartis Kisqali® NATALEE Data Show Durable Reduction in Recurrence in Early Breast Cancer

    Details:

    Kisqali (ribociclib) is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.


    Lead Product(s): Ribociclib

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable December 10, 2024

    blank

    10

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    NextGen Biomed
    Not Confirmed

    Novartis Pharmaceuticals Corporation

    Switzerland
    arrow
    NextGen Biomed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Ribociclib

    Therapeutic Area : Oncology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Novartis Kisqali® NATALEE Data Show Durable Reduction in Recurrence in Early Breast Cancer

    Details : Kisqali (ribociclib) is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.

    Product Name : Undisclosed

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    December 10, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDA Orange Book

    read-more
    read-more

    Europe

    read-more
    read-more

    01

    Brand Name : Myfortic

    Switzerland
    Immuno
    Not Confirmed
    arrow

    Brand Name : Myfortic

    Switzerland
    arrow
    Immuno
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : Switzerland

    Acidum mycophenolicum

    Novartis Pharmaceuticals Corporation

    Dosage Form : Film-Coated Tablets

    Dosage Strength : 180mg

    Packaging :

    Brand Name : Myfortic

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Switzerland

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Brand Name : Myfortic

    Switzerland
    Immuno
    Not Confirmed
    arrow

    Brand Name : Myfortic

    Switzerland
    arrow
    Immuno
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : Switzerland

    Acidum mycophenolicum

    Novartis Pharmaceuticals Corporation

    Dosage Form : Film-Coated Tablets

    Dosage Strength : 360mg

    Packaging :

    Brand Name : Myfortic

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Switzerland

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Brand Name : Zometa

    Switzerland
    Immuno
    Not Confirmed
    arrow

    Brand Name : Zometa

    Switzerland
    arrow
    Immuno
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : Switzerland

    Acidum zoledronicum

    Novartis Pharmaceuticals Corporation

    Dosage Form : Inf Conc

    Dosage Strength : 4mg/5ml

    Packaging :

    Brand Name : Zometa

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Switzerland

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Brand Name : Piqray

    Switzerland
    Immuno
    Not Confirmed
    arrow

    Brand Name : Piqray

    Switzerland
    arrow
    Immuno
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : Switzerland

    Alpelisibum

    Novartis Pharmaceuticals Corporation

    Dosage Form : Film-Coated Tablets

    Dosage Strength : 150mg

    Packaging :

    Brand Name : Piqray

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Switzerland

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Brand Name : Piqray

    Switzerland
    Immuno
    Not Confirmed
    arrow

    Brand Name : Piqray

    Switzerland
    arrow
    Immuno
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : Switzerland

    Alpelisibum

    Novartis Pharmaceuticals Corporation

    Dosage Form : Film-Coated Tablets

    Dosage Strength : 150mg

    Packaging :

    Brand Name : Piqray

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Switzerland

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Brand Name : Piqray

    Switzerland
    Immuno
    Not Confirmed
    arrow

    Brand Name : Piqray

    Switzerland
    arrow
    Immuno
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : Switzerland

    Alpelisibum

    Novartis Pharmaceuticals Corporation

    Dosage Form : Filmtabl

    Dosage Strength : 200mg

    Packaging :

    Brand Name : Piqray

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Switzerland

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Brand Name : Piqray

    Switzerland
    Immuno
    Not Confirmed
    arrow

    Brand Name : Piqray

    Switzerland
    arrow
    Immuno
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : Switzerland

    Alpelisibum

    Novartis Pharmaceuticals Corporation

    Dosage Form : Filmtabl

    Dosage Strength : 200mg+50mg

    Packaging :

    Brand Name : Piqray

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Switzerland

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    Brand Name : Piqray

    Switzerland
    Immuno
    Not Confirmed
    arrow

    Brand Name : Piqray

    Switzerland
    arrow
    Immuno
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : Switzerland

    Alpelisibum

    Novartis Pharmaceuticals Corporation

    Dosage Form : Filmtabl

    Dosage Strength : 200mg+50mg

    Packaging :

    Brand Name : Piqray

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Switzerland

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    Brand Name : Symmetrel

    Switzerland
    Immuno
    Not Confirmed
    arrow

    Brand Name : Symmetrel

    Switzerland
    arrow
    Immuno
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : Switzerland

    Amantadine hydrochloridum

    Novartis Pharmaceuticals Corporation

    Dosage Form : Kaps

    Dosage Strength : 100mg

    Packaging :

    Brand Name : Symmetrel

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Switzerland

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Brand Name : Exforge

    Switzerland
    Immuno
    Not Confirmed
    arrow

    Brand Name : Exforge

    Switzerland
    arrow
    Immuno
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : Switzerland

    Amlodipine; Valsartan

    Novartis Pharmaceuticals Corporation

    Dosage Form : Filmtabl

    Dosage Strength : 10mg/160mg

    Packaging :

    Brand Name : Exforge

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Switzerland

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Australia

    read-more
    read-more

    01

    Brand Name : Tears Naturale

    U.S.A
    NextGen Biomed
    Not Confirmed
    arrow

    Brand Name : Tears Naturale

    U.S.A
    arrow
    NextGen Biomed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : Australia

    dextran-70 + hypromellose

    Alcon Inc

    Dosage Form : Eye Drop; Eye Drop

    Dosage Strength : 1MG/1ML; 3MG/1ML

    Packaging : 1

    Brand Name : Tears Naturale

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Australia

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Brand Name : Poly-Tears

    U.S.A
    NextGen Biomed
    Not Confirmed
    arrow

    Brand Name : Poly-Tears

    U.S.A
    arrow
    NextGen Biomed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : Australia

    dextran-70 + hypromellose

    Alcon Inc

    Dosage Form : Eye Drop; Eye Drop

    Dosage Strength : 1MG/1ML; 3MG/1ML

    Packaging : 1

    Brand Name : Poly-Tears

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Australia

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Brand Name : Tears Naturale

    U.S.A
    NextGen Biomed
    Not Confirmed
    arrow

    Brand Name : Tears Naturale

    U.S.A
    arrow
    NextGen Biomed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : Australia

    dextran-70 + hypromellose

    Alcon Inc

    Dosage Form : Eye Drop; Eye Drop

    Dosage Strength : 1MG/1ML; 3MG/1ML

    Packaging : 1

    Brand Name : Tears Naturale

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Australia

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Brand Name : Poly-Tears

    U.S.A
    NextGen Biomed
    Not Confirmed
    arrow

    Brand Name : Poly-Tears

    U.S.A
    arrow
    NextGen Biomed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : Australia

    dextran-70 + hypromellose

    Alcon Inc

    Dosage Form : Eye Drop; Eye Drop

    Dosage Strength : 1MG/1ML; 3MG/1ML

    Packaging : 1

    Brand Name : Poly-Tears

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Australia

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Brand Name : Tears Naturale

    U.S.A
    NextGen Biomed
    Not Confirmed
    arrow

    Brand Name : Tears Naturale

    U.S.A
    arrow
    NextGen Biomed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : Australia

    dextran-70 + hypromellose

    Alcon Inc

    Dosage Form : Eye Drop; Eye Drop

    Dosage Strength : 1MG/1ML; 3MG/1ML

    Packaging : 1

    Brand Name : Tears Naturale

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Australia

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Brand Name : Poly-Tears

    U.S.A
    NextGen Biomed
    Not Confirmed
    arrow

    Brand Name : Poly-Tears

    U.S.A
    arrow
    NextGen Biomed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : Australia

    dextran-70 + hypromellose

    Alcon Inc

    Dosage Form : Eye Drop; Eye Drop

    Dosage Strength : 1MG/1ML; 3MG/1ML

    Packaging : 1

    Brand Name : Poly-Tears

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Australia

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Brand Name : Genteal

    U.S.A
    NextGen Biomed
    Not Confirmed
    arrow

    Brand Name : Genteal

    U.S.A
    arrow
    NextGen Biomed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : Australia

    hypromellose

    Alcon Inc

    Dosage Form :

    Dosage Strength :

    Packaging : 1

    Brand Name : Genteal

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Australia

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    Brand Name : In a Wink Moisturisi...

    U.S.A
    NextGen Biomed
    Not Confirmed
    arrow

    Brand Name : In a Wink Moisturisi...

    U.S.A
    arrow
    NextGen Biomed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : Australia

    hypromellose

    Alcon Inc

    Dosage Form :

    Dosage Strength :

    Packaging : 1

    Brand Name : In a Wink Moisturising

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Australia

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    Brand Name : Genteal

    U.S.A
    NextGen Biomed
    Not Confirmed
    arrow

    Brand Name : Genteal

    U.S.A
    arrow
    NextGen Biomed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : Australia

    hypromellose

    Alcon Inc

    Dosage Form :

    Dosage Strength :

    Packaging : 1

    Brand Name : Genteal

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Australia

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Brand Name : Genteal

    U.S.A
    NextGen Biomed
    Not Confirmed
    arrow

    Brand Name : Genteal

    U.S.A
    arrow
    NextGen Biomed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : Australia

    hypromellose

    Alcon Inc

    Dosage Form :

    Dosage Strength :

    Packaging : 1

    Brand Name : Genteal

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Australia

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Listed Dossiers

    read-more
    read-more

    01

    Brand Name : Fluorescite

    U.S.A
    Immuno
    Not Confirmed
    arrow

    Brand Name : Fluorescite

    U.S.A
    arrow
    Immuno
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country : U.S.A

    Fluorescein Sodium

    Alcon Inc

    Dosage Form : Solution for injection

    Brand Name : Fluorescite

    Dosage Strength : 10%

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : U.S.A

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Brand Name : Isturisa

    Switzerland
    Immuno
    Not Confirmed
    arrow

    Brand Name : Isturisa

    Switzerland
    arrow
    Immuno
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country :

    Osilodrostat

    Novartis Pharmaceuticals Corporation

    Dosage Form : Tablet

    Brand Name : Isturisa

    Dosage Strength : 1MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country :

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Brand Name : Isturisa

    Switzerland
    Immuno
    Not Confirmed
    arrow

    Brand Name : Isturisa

    Switzerland
    arrow
    Immuno
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country :

    Osilodrostat

    Novartis Pharmaceuticals Corporation

    Dosage Form : Tablet

    Brand Name : Isturisa

    Dosage Strength : 5MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country :

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Brand Name : Isturisa

    Switzerland
    Immuno
    Not Confirmed
    arrow

    Brand Name : Isturisa

    Switzerland
    arrow
    Immuno
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info :

    Registration Country :

    Osilodrostat

    Novartis Pharmaceuticals Corporation

    Dosage Form : Tablet

    Brand Name : Isturisa

    Dosage Strength : 10MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country :

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Excipients

    Click here to find the perfect excipient manufacturers by their capabilities

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Novartis Pharmaceuticals Corporation and get a quotation

    Novartis Pharmaceuticals Corporation is a supplier offers 41 products (APIs, Excipients or Intermediates).

    Find a price of Pentetreotide bulk with DMF, JDMF offered by Novartis Pharmaceuticals Corporation

    Find a price of Valsartan bulk with DMF, CEP offered by Novartis Pharmaceuticals Corporation

    Find a price of Amlodipine Besylate bulk with CEP offered by Novartis Pharmaceuticals Corporation

    Find a price of Baclofen bulk with DMF offered by Novartis Pharmaceuticals Corporation

    Find a price of Cefepime Hydrochloride bulk with JDMF offered by Novartis Pharmaceuticals Corporation

    Find a price of Ceftriaxone bulk with JDMF offered by Novartis Pharmaceuticals Corporation

    Find a price of Cyclosporine bulk with JDMF offered by Novartis Pharmaceuticals Corporation

    Find a price of Fluvastatin bulk with DMF offered by Novartis Pharmaceuticals Corporation

    Find a price of Glycolide - lactide copolymer bulk with DMF offered by Novartis Pharmaceuticals Corporation

    Find a price of Letrozole bulk with CEP offered by Novartis Pharmaceuticals Corporation

    Find a price of NAFTIFINE HCL bulk with DMF offered by Novartis Pharmaceuticals Corporation

    Find a price of Penicillin G Benzathine bulk with JDMF offered by Novartis Pharmaceuticals Corporation

    Find a price of Terbinafine bulk with DMF offered by Novartis Pharmaceuticals Corporation

    Find a price of Topotecan Hydrochloride bulk with DMF offered by Novartis Pharmaceuticals Corporation

    Find a price of Benzonatate bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Bisoctrizole bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Chlorthalidone bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Clofazimine bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Clomipramine Hydrochloride bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Edotreotide bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Eudragit Rs bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Methylphenidate Hydrochloride bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Naphazoline Hydrochloride bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Pyrilamine bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Pyrilamine Maleate bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Rifampicin bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of Thurfyl Nicotinate bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of STARTING MATERIALS 1 & 3, IN NEW JERSEY AND SWITZERLAND bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of CGP LL637 ADJUVANT--CHEMISTRY & GMP bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of PULMOSPHERE(R) PLACEBO INHALATION POWDER bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL AND OPERATING PROCEDURES IN STEIN, SWITZERLAND. bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of TESSALON DRUG SUBSTANCE bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of CGP 17,582B bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of PERSONNEL, FACILS & GEN OPERATING PROCEDURES AT EAST HANOVER, NJ. bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of 2(2'-HYDROXY-5-METHYLPHENYL) BENZOTRIAZOLE bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURE IN ORLEANS-LA SOURCE, FRANCE. bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN GRIMSBY, UK bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of ADJUVANT CGP 11637:TOXICITY STUDIES & RESULTS CONDUCTED IN EUROPEAN FA bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of PULMONARY DRUG DELIVERY SYSTEM (PDDS) CLINICAL bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of TINUVIN 326 bulk offered by Novartis Pharmaceuticals Corporation

    Find a price of FACILITY AND OPERATING PROCEDURES IN DORVAL, QUEBEC, CANADA bulk offered by Novartis Pharmaceuticals Corporation

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search